Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Hernando Lopez"'
Publikováno v:
Frontiers in Genetics, Vol 15 (2024)
The current median survival for glioblastoma (GBM) patients is only about 16 months, with many patients succumbing to the disease in just a matter of months, making it the most common and aggressive primary brain cancer in adults. This poor outcome i
Externí odkaz:
https://doaj.org/article/79ddda6b0fa9404fb7a201e22fb63f43
Autor:
Daqian Zhan, Fatih Yalcin, Ding Ma, Yi Fu, Shuang Wei, Bachchu Lal, Yunqing Li, Omar Dzaye, John Laterra, Mingyao Ying, Hernando Lopez-Bertoni, Shuli Xia
Publikováno v:
Genes and Diseases, Vol 9, Iss 3, Pp 717-730 (2022)
Glioblastoma (GBM, WHO grade IV glioma) is the most common and lethal malignant brain tumor in adults with a dismal prognosis. The extracellular matrix (ECM) supports GBM progression by promoting tumor cell proliferation, migration, and immune escape
Externí odkaz:
https://doaj.org/article/a5a043bb29f6446ea101dbfafff3a3ee
Autor:
Hernando Lopez-Bertoni, Amanda Johnson, Yuan Rui, Bachchu Lal, Sophie Sall, Maureen Malloy, Jonathan B. Coulter, Maria Lugo-Fagundo, Sweta Shudir, Harmon Khela, Christopher Caputo, Jordan J. Green, John Laterra
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 7, Iss 1, Pp 1-12 (2022)
Abstract DNA methylation is a reversible process catalyzed by the ten–eleven translocation (TET) family of enzymes (TET1, TET2, TET3) that convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). Altered patterns of 5hmC and 5mC are widely
Externí odkaz:
https://doaj.org/article/c6cf026f792b49c69fedffbfcee29718
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Despite its growing use in cancer treatment, immunotherapy has been virtually ineffective in clinical trials for gliomas. The inherently cold tumor immune microenvironment (TIME) in gliomas, characterized by a high ratio of pro-tumor to anti-tumor im
Externí odkaz:
https://doaj.org/article/5cf6b9a7d58a4246a2ecba8d6af7169f
Autor:
Hernando Lopez-Bertoni, John Laterra
Publikováno v:
Translational Oncology, Vol 14, Iss 6, Pp 101064- (2021)
Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics
Externí odkaz:
https://doaj.org/article/df3b618c98fa4275a99b875ac3c99e49
Autor:
Jonathan B. Coulter, Hernando Lopez-Bertoni, Katherine J. Kuhns, Richard S. Lee, John Laterra, Joseph P. Bressler
Publikováno v:
Epigenetics, Vol 12, Iss 10, Pp 854-864 (2017)
Recent studies have shown that loss of TET1 may play a significant role in the formation of tumors. Because genomic instability is a hallmark of cancer, we examined the potential involvement of 10-11 translocation 1 (TET1) in the DNA damage response
Externí odkaz:
https://doaj.org/article/10b62dc99e4b4a36a4a9e11839850d2e
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e32313 (2012)
Pure nucleotide precursor pools are a prerequisite for high-fidelity DNA replication and the suppression of mutagenesis and carcinogenesis. ITPases are nucleoside triphosphate pyrophosphatases that clean the precursor pools of the non-canonical triph
Externí odkaz:
https://doaj.org/article/9d156e07f50f49c081012ac857b3488d
Autor:
Monreal, Manuel, Decousus, Hervè, Prandoni, Paolo, Brenner, Benjamin, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Wells, Philip, Papadakis, Manolis, Aibar, M.A., Alfonso, M., Asensio-Cruz, M.I., Auguet, T., Arcelus, J.I., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Bueso, T., Cañas, I., Ceausu, A., Chic, N., Culla, A., del Pozo, R., del Toro, J., Díaz-Pedroche, M.C., Díaz-Peromingo, J.A., Duffort, M., Elias-Hernández, T., Falgá, C., Fernández-Aracil, C., Fernández-Capitán, C., Fidalgo, M.A., Font, C., Font, L., Gallego, P., García, M.A., García-Bragado, F., García-Rodenas, M., Gómez, V., González, J., Grau, E., Grimón, A., Guijarro, R., Guirado, L., Gutiérrez, J., Hernández-Comes, G., Hernández-Blasco, L., Hernando-López, E., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Joya, M.D., Llamas, P., Lecumberri, R., Lobo, J.L., López-Jiménez, L., López-Reyes, R., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Maestre, A., Marchena, P.J., Martín, M., Martín-Martos, F., Monreal, M., Nieto, J.A., Nieto, S., Núñez, A., Núñez, M.J., Odriozola, M., Otalora, S., Otero, R., Ovejero, A., Pedrajas, J.M., Pérez, G., Pérez-Ductor, C., Peris, M.L., Porras, J.A., Reig, O., Riera-Mestre, A., Riesco, D., Rivas, A., Rodríguez-Dávila, M.A., Rosa, V., Ruiz-Artacho, P., Ruiz-Giménez, N., Sahuquillo, J.C., Sala-Sainz, M.C., Sampériz, A., Sánchez, R., Sanz, O., Soler, S., Sopeña, B., Suriñach, J.M., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vicente, P., Vidal, G., Villalobos, A., Villalta, J., Vanassche, T., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Salgado, E., Bertoletti, L., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahé, I., Merah, A., Moustafa, F., Papadakis, M., Braester, A., Brenner, B., Tzoran, I., Antonucci, G., Barillari, G., Bertone, A., Bilora, F., Bortoluzzi, C., Ciammaichella, M., Di Girolamo, C., Di Micco, P., Duce, R., Ferrazzi, P., Giorgi-Pierfranceschi, M., Grandone, E., Lodigiani, C., Maida, R., Mastroiacovo, D., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Visonà, A., Zalunardo, B., Drucka, E., Kigitovica, D., Skride, A., Sousa, M.S., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Jara-Palomares, Luis, Otero, Remedios, Jimenez, David, Carrier, Marc, Margeli, Mireia, Praena-Fernandez, Juan Manuel, Grandone, Elvira
Publikováno v:
In Chest March 2017 151(3):564-571
Autor:
Shuli Xia, Hernando Lopez-Bertoni, Alan Meeker, Yunqing Li, Mingyao Ying, John Laterra, Charles Eberhart, Yi Fu, Bachchu Lal, Shuang Wei, Ding Ma, Daqian Zhan
Heterozygous isocitrate dehydrogenase (IDH) R132H mutation (IDH1R132H/WT) is an early event during gliomagenesis. Clinically, patients with glioma carrying mutant IDH1 respond better to antitumor therapies. However, the mechanism by which IDH1 mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::682c284acfcb91ec55ff1ce01a632820
https://doi.org/10.1158/1541-7786.c.6545270.v1
https://doi.org/10.1158/1541-7786.c.6545270.v1
Autor:
Shuli Xia, Hernando Lopez-Bertoni, Alan Meeker, Yunqing Li, Mingyao Ying, John Laterra, Charles Eberhart, Yi Fu, Bachchu Lal, Shuang Wei, Ding Ma, Daqian Zhan
Supplementary Table 1. Primers used for qRT-PCR Supplementary Fig. 1. Heterozygous IDH1R132H/WT enhanced therapy-induced senescence in glioma cells. Supplementary Fig. 2. a. Schematic graph of genome editing strategy with two guide RNAs to knock out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c7a77d9f6ac5d15ed2eff1238245ee
https://doi.org/10.1158/1541-7786.22526966
https://doi.org/10.1158/1541-7786.22526966